Invisicare Enhances the Delivery of Topical Medical Marijuana in New Product Line
LAS VEGAS, NV / ACCESSWIRE / September 15, 2016 / Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), developers of patented
Invisicare® polymer delivery systems, announces it has licensed the exclusive world rights to its topical and transdermal cannabis
products formulated with Invisicare to CannaSkin, LLC, a cannabis product licensing company with international contacts in the
medical marijuana industry.
CannaSkin has the exclusive license to manufacture, market and sub-license Skinvisible's new cannabis products. Their targets
will initially include facilities in the 25 US jurisdictions currently approved for medical marijuana as well as Canada and Israel
where there is a great demand for cannabis products supported by science.
Skinvisible will utilize its patented skin delivery system Invisicare to formulate and deliver high-quality topical cannabinoid
products containing CBD and THC. CBD has proven to have many therapeutic effects and it does not produce the "high" associated with
THC. Cannabinoids have been used to treat many skin conditions, from acne, eczema, psoriasis, skin cancer, to anti-aging, due to
their anti-oxidant and anti-inflammatory properties. Skinvisible's Invisicare technology allows for the superior binding of these
products to the skin, a controlled release of the cannabinoids both topically and transdermally, as well as providing patent
protection.
"We are excited to enter into the emerging global cannabis market with CannaSkin, an extremely qualified partner in the cannabis
industry," said Terry Howlett, President of Skinvisible. "Skinvisible will bring a new era of cannabis products; ones supported by
science and patents. Our objective is to provide superior products with many options for medical marijuana consumers."
There is rapid growth in the number of legalized marijuana jurisdictions in the USA and internationally and with that, revenues
growing at an exponential rate. According to AcrView Market Research, legal US cannabis sales are projected to increase by 25% in
2016 to $6.7 billion.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented
polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare
holds active ingredients on the skin for extended periods of time along with controlling the release of actives. Kintari Int. Inc.,
a wholly-owned subsidiary markets its cosmeceutical and OTC products.
www.skinvisible.com www.invisicare.com
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe
harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form
10Q for the period ending June 30, 2016).
Contact:
Doreen McMorran, Skinvisible Inc. info@skinvisible.com Phone: 702-433-7154
SOURCE: Skinvisible Pharmaceuticals, Inc.
